Zhitong Finance App News, Hehuang Pharmaceutical (00013.HK) issued an announcement. Hewang Pharmaceutical (China) Co., Ltd. (HUTCHMED or HUTCHMED for short) announced the positive results of the SAFFRON Global Phase III study today. In patients with epidermal growth factor receptor (EGFR) -mutated non-small cell lung cancer, the combination therapy with orpathys® (ORPATHYS®, savolitinib) and Teresa® (TAGRISSO®, osimertinib) showed statistically and clinically significant improvements in progression-free survival (PFS) and overall survival (OS) compared to platinum dual-agent chemotherapy. The tumors in the study were accompanied by high levels of MET overexpression or amplification, and the disease progressed after previous treatment with Teresa®.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.